Successful Results After 3 Years' Tacrolimus Immunosuppression in ABO-Incompatible Kidney Transplantation Recipients in Japan

between the ABO-compatible and -incompatible groups (P .001). Patient and graft survival rates by patient age for ABO-incompatible cases did not show any statistically significant differences between patients 30 years and those 30 years, though there was a favorable trend toward better graft survival in patients 30 years. Dosing and Trough Levels The mean (range) doses of tacrolimus (mg/day) were 6.0 (4.0 to 9.0) at 1 year, 5.5 (4.0 to 9.0) at 2 years, and 4.0 (3.6 to 7.1) at 3 years in recipients of ABO-incompatible grafts, and 6.0 (4.0 to 9.0) at 1 year, 5.0 (4.0 to 8.0) at 2 years, and 5.0 (4.0 to 8.0) at 3 years in those with ABO-compatible grafts. The mean (range) whole blood trough levels of tacrolimus (ng/mL) were 6.4 (5.3 to 9.4) at 1 year, 7.1 (5.3 to 9.2) at 2 years, and 6.1 (4.2 to 9.1) at 3 years in recipients of ABO-incompatible grafts, and 7.1 (5.4 to 9.4) at 1 year, 6.3 (5.0 to 8.3) at 2 years, and 5.9 (4.5 to 8.1) at 3 years in those with ABO-compatible grafts. The whole blood trough levels of tacrolimus over 3 years posttransplantation were almost comparable between the recipients with ABO-compatible grafts and those with ABO-incompatible grafts. There was no significant difference in tacrolimus trough level between ABO-compatible and -incompatible recipients.